NCT06336356View on ClinicalTrials.gov

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions
Uncontrolled Hypertension
Interventions
DRUG

Baxdrostat

Baxdrostat will be administered orally once daily.

DRUG

Placebo

Placebo will be administered orally once daily.

Trial Locations (10)

23502

Research Site, Norfolk

33612

Research Site, Tampa

60643

Research Site, Chicago

70006

Research Site, Metairie

77074

Research Site, Houston

77099

Research Site, Houston

85018

Research Site, Phoenix

85281

Research Site, Tempe

91356

Research Site, Tarzana

91763

Research Site, Montclair

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY